ArticleCell communication and signaling : CCS2025
PLA2 driven lipid signaling drives ARMS tumorigenic cell properties.
Article in Cell communication and signaling : CCS, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Meeting report: the inaugural muscle biology and cachexia conference at the University of Houston, May 18-20, 2025, Houston, Texas, USA.Frontiers in physiology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
backgroundAdvancements in chemotherapy have improved outcomes for rhabdomyosarcoma (RMS), the most common soft tissue sarcoma in children. However, relapse-free survival rates remain below 20% in metastatic alveolar rhabdomyosarcoma (ARMS). Tumor-initiating cells (TICs) drive recurrence. Targeting this pool of cells has been shown to reduce relapse rates and metastasis in various cancers. Emerging evidence implicates lipid metabolism in supporting stem-like properties in cancer. However, TICs remain poorly characterized in ARMS. This study investigates the transcriptomic and metabolic profile of TICs in ARMS.
methodsTranscriptomic and lipidomic profiling were performed on tumorsphere-derived and adherent cells from ARMS cells. Differential expression of metabolic genes and lipid species was assessed via RNA-Sequencing and mass spectrometry. Functional dependence on Phospholipase A2 (PLA2) signaling was tested on TICs in vitro and in vivo. Seahorse assays were used to measure glycolytic and mitochondrial flux. Statistical significance was determined using Student's t-test or one-way ANOVA.
resultsTranscriptomic analysis of ARMS tumorspheres showed upregulation of lipid metabolism especially different PLA2 enzyme subtypes, and suppression of glycolytic gene expression. Lipidomic analyses revealed enrichment of linoleic acid-derived triglycerides and lysophospholipids, paralleled by increased PLA2 activity. Tumorspheres also showed elevated expression of lipid storage regulators PPARG and CD36 and correspondingly, significant lipid droplet accumulation. Inhibition of PLA2 with Darapladib reduced tumorsphere formation and cellular motility in vitro and tumor volume in vivo. These defects were rescued by exogenous linoleic acid (LA) supplementation, implicating PLA2-driven lipid signalling in TIC maintenance. Interestingly, TICs display high metabolic flexibility in energy consumption, as neither glycolysis nor fatty acid oxidation (FAO) inhibition significantly impaired tumorsphere formation.
conclusionsPLA2-mediated lipid remodelling supports TIC by promoting linoleic acid-linked lipid signalling. PLA2 inhibition impairs self-renewal, motility, and tumorigenic potential, highlighting it as a promising therapeutic target in ARMS. These findings uncover lipid remodelling as a key metabolic adaptation in ARMS TICs, independent of canonical energy pathways, with implications for targeting the stem-like compartment in pediatric sarcomas.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.